Background Economic protection against the cost of unforeseen ill health has become a global concern as expressed in the 2005 World Health Assembly resolution (WHA58. care financing in this paper. Results Ghana’s health care financing system is generally progressive. The progressivity of health financing is usually driven largely by the overall progressivity of taxes, which account for close to 50% of health care funding. The national health insurance (NHI) levy (part of VAT) is definitely mildly progressive and formal sector NHI payroll deductions will also be progressive. However, informal sector NHI contributions were found to be regressive. Out-of-pocket payments, which account for 45% of funding, are regressive form of health payment to households. Bottom line For Ghana to achieve sufficient economic risk security and obtain general insurance eventually, it needs to increase pre-payment cover to all or any in the casual sector, through financing their efforts completely from taxes perhaps, and address various other issues impacting the expansion SNX-5422 from the National MEDICAL HEALTH INSURANCE. Furthermore, the pre-payment financing pool for healthcare needs to develop therefore budgetary allocation to medical sector could be enhanced. Background Healthcare financing strategies possess been recently provided better priority in worldwide wellness policy analysis and debates [1]. A consensus is normally emerging on the necessity for developing countries to go towards universal insurance through pre-payment funding mechanisms, considering that consumer fees as well as SNX-5422 other immediate payments experienced and continue steadily to have unwanted effects, on poor people and households [2 especially,3]. Consumer costs and direct obligations have an effect on the indegent disproportionately. Unfortunately exemptions which were introduced to attempt to cushion the consequences of consumer fees have didn’t protect the indegent from catastrophic healthcare costs to the idea that 84% of these qualified to receive exemptions in Ghana SNX-5422 hardly ever got them [4]. Proof also implies that getting rid of consumer costs, as some advocate, isn’t a sustainable answer to health care funding. It must be supported by way of a simultaneous upsurge in financing through pre-payment systems [5]. There’s a developing dependence on developing countries as a result, in Africa particularly, to ensure reasonable financing within their wellness systems, and offer universal insurance with financial security because of their populations if they’re to attain the health-related MDG goals by 2015 (that is significantly less than five years apart). That has regarded this want and in its Globe Health Assembly quality WHA58.33 known as on all member state governments to “program the changeover to universal insurance of their people” [6]. Identifying a combination of Rabbit Polyclonal to PIK3C2G health care financing mechanisms that would provide the needed access to health care services for those citizens is best informed by understanding how the burden of health care financing currently falls on different segments of the population. Although there is a commitment to going after a universal health system in Ghana, no assessment of equity in health care financing has been undertaken. To improve equity in health care financing and promote the goal of achieving universal protection, there is a need to measure the degree of progressivity of existing health care financing mechanisms to be able SNX-5422 to set up the relative funding burden on the poor compared with the rich. This will allow us to identify which health care financing strategies are regressive (i.e. place a greater burden on the poor) and which are progressive (i.e. the rich contribute a higher proportion of their income than the poor). SNX-5422 It will therefore provide insights into which financing mechanisms best provide financial safety and promote common protection. The paper therefore seeks to investigate the degree to which paying for health care relates to people’s ability to pay and to investigate.
Background Economic protection against the cost of unforeseen ill health has
Categories
- 34
- 5- Receptors
- A2A Receptors
- ACE
- Acetylcholinesterase
- Adenosine Deaminase
- Adenylyl Cyclase
- Adrenergic ??2 Receptors
- Alpha2 Adrenergic Receptors
- Annexin
- Antibiotics
- ATPase
- AXOR12 Receptor
- Ca2+ Ionophore
- Cannabinoid
- Cannabinoid (GPR55) Receptors
- CB2 Receptors
- CCK Receptors
- Cell Metabolism
- Cell Signaling
- Cholecystokinin2 Receptors
- CK1
- Corticotropin-Releasing Factor1 Receptors
- DHCR
- DMTases
- DNA Ligases
- DNA Methyltransferases
- Dopamine D1 Receptors
- Dopamine D3 Receptors
- Dopamine D4 Receptors
- Endothelin Receptors
- EP1-4 Receptors
- Epigenetics
- Exocytosis & Endocytosis
- Fatty Acid Synthase
- Flt Receptors
- GABAB Receptors
- GIP Receptor
- Glutamate (Kainate) Receptors
- Glutamate (Metabotropic) Group III Receptors
- Glutamate (NMDA) Receptors
- Glutamate Carboxypeptidase II
- Glycogen Phosphorylase
- Glycosyltransferase
- GnRH Receptors
- Heat Shock Protein 90
- hERG Channels
- Hormone-sensitive Lipase
- IKK
- Imidazoline Receptors
- IMPase
- Inositol Phosphatases
- Kisspeptin Receptor
- LTA4 Hydrolase
- M1 Receptors
- Matrixins
- Melastatin Receptors
- mGlu Group III Receptors
- mGlu5 Receptors
- Monoamine Oxidase
- Motilin Receptor
- My Blog
- Neutrophil Elastase
- Nicotinic (??4??2) Receptors
- NKCC Cotransporter
- NMU Receptors
- Nociceptin Receptors
- Non-Selective
- Non-selective 5-HT
- OP3 Receptors
- Opioid, ??-
- Orexin2 Receptors
- Other
- Other Oxygenases/Oxidases
- Other Transcription Factors
- p38 MAPK
- p53
- p56lck
- PAF Receptors
- PDPK1
- PKC
- PLA
- PPAR
- PPAR??
- Proteasome
- PTH Receptors
- Ras
- RNA Polymerase
- Serotonin (5-HT2B) Receptors
- Serotonin Transporters
- Sigma2 Receptors
- Sodium Channels
- Steroid Hormone Receptors
- Tachykinin NK1 Receptors
- Tachykinin NK2 Receptors
- Tachykinin, Non-Selective
- Telomerase
- Thyrotropin-Releasing Hormone Receptors
- Topoisomerase
- trpp
- Uncategorized
- USP
Recent Posts
- 2012) using the Phenotypic Characteristic Search for human strains with markers for resistance to Adamantane, Oseltamivir, or both drugs
- Tissue were homogenized into single-cell suspensions and put through red bloodstream cell lysis
- A phase I/II study investigated the safety and efficacy of concurrent local palliative RT and durvalumab (PD-L1 inhibitor) in 10 patients with unresectable or metastatic advanced solid tumors [136]
- We believe that this hypothesis-generating study could open new avenues for exploring oxidative stress as a potential pathogenetic and, hypothetically, therapeutic target for mitigating CLL strong class=”kwd-title” Keywords: Leukemia, Lymphocytic, Gilbert’s, Syndrome Gilbert’s syndrome (GS) is the most common inherited disorder of bilirubin glucuronidation
- Such costs aren’t simple for tertiary-care hospitals in growing countries sometimes, since these already are powered by minimal budget which switches into provision of fundamental medical services mostly, laboratory, radiology, pharmacy services, and bed space
Tags
a 67 kDa type I transmembrane glycoprotein present on myeloid progenitors
and differentiation. The protein kinase family is one of the largest families of proteins in eukaryotes
Apoptosis
bladder
brain
breast
cell cycle progression
cervix
CSP-B
Cyproterone acetate
EGFR) is the prototype member of the type 1 receptor tyrosine kinases. EGFR overexpression in tumors indicates poor prognosis and is observed in tumors of the head and neck
EM9
endometrium
erythrocytes
F3
Goat polyclonal to IgG H+L)
Goat polyclonal to IgG H+L)Biotin)
GRK4
GSK1904529A
Igf1
Mapkap1
monocytes andgranulocytes. CD33 is absent on lymphocytes
Mouse monoclonal to CD33.CT65 reacts with CD33 andtigen
Palomid 529
platelets
PTK) or serine/threonine
Rabbit Polyclonal to ARNT.
Rabbit polyclonal to BMPR2
Rabbit Polyclonal to CCBP2.
Rabbit Polyclonal to EDG4
Rabbit polyclonal to EIF4E.
Rabbit polyclonal to IL11RA
Rabbit polyclonal to LRRIQ3
Rabbit Polyclonal to MCM3 phospho-Thr722)
Rabbit Polyclonal to RBM34
SB 216763
SKI-606
SNX-5422
STK) kinase catalytic domains. Epidermal Growth factor receptor
stomach
stomach and in squamous cell carcinoma.
TNFSF8
TSHR
VEGFA
vulva